knowledge -WSS

knowledge

author：entertainment 2025-08-23 08:57:40 - browse：9625

Moderna chairman Noubar Afeyan exuded star power earlier this month as he commanded the spotlight at BIO 2023, the industry’s largest convention.

Basking in the accolades heaped on Moderna’s celebrated Covid-19 vaccine, Afeyan regaled the Boston audience with the company’s origin story and greeted fans who lined up to snap selfies with him. Stuart Cable, a partner in the law firm Goodwin who’s represented Moderna and joined Afeyan on stage, called Moderna “arguably the most successful story in the history of biotechnology.”

But the Cambridge, Mass.-based company can’t afford to rest on its laurels. Two and a half years after its vaccine liberated tens of millions from pandemic lockdowns — ringing up more than $36 billion in sales so far — Moderna faces a changing business and regulatory environment. Demand for Covid shots is waning, a backlash over drug prices is gaining traction, and questions about its next act loom.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： A new approach to psychiatric drug development

WSS

Longer MASH drug regimen improved liver, Akero study finds

Why Talkspace is targeting Medicare, a tricky market

First over

Health tech startups drop sharply from 2021 highs

For AI in health care standards, federal regulators join with industry group

Ozempic has benefits for kidney disease as well as diabetes

focus

knowledge

hotspot

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Families look for replacement for GSK asthma drug Flovent

Moonlake's readout produced a cash windfall. Risks remain

Paxlovid should be available without a positive Covid test

Trump demands the U.S. pay no more for drugs than other countries … again

The untold story of TV’s first prescription drug ad

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Florida health officials providing scant details on measles cases

After affirmative action ruling, medical educators look to 'holistic review'

Sudafed saga points to U.S. issues with evaluating older drugs

hotspot

Ancient Greek ideas underpin modern concepts of pregnancy

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

Menendez indictment could see pharma lose a key ally

Medicare drug price negotiation program allowed for now

Change Healthcare: What is it, why does its cyberattack matter?

WHO recommends dropping component of many flu vaccines

focus

focus

explore

focus